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Background: Candidemia results in substantial morbidity
and mortality and species distribution and its suscepti-
bility proﬁle should be locally monitored. Antifungigram
still a challenge but few laboratories have microdilution
techniques in Latin America, in a routine basis, and other
methodologies should be evaluated.
Methods: Epidemiological data from candidemia episodes
were collected during 2006 in a large teaching hospital. Inci-
dence was calculated by 1,000 admission and 1,000 patient
days.
Minimal inhibitory concentrations (MIC) were determined
using Sensititre Yeast-One Y8, and E-test. The follow-
ing drugs were tested: amphotericin B (AMB); caspofungin
(CAS); posaconazole (POS), ﬂuconazole (FLU), Itraconazol
(ITRA) and voriconazole (VOR). The disk diffusion method
was also performed for FLU and VOR according to CLSI.
Results: One hundred and thirty-six cases of candidemia
were identiﬁed and represented 3.5% of the overall pos-
itive blood cultures. Incidence was 1.87 cases per 1,000
admissions and 0.27 cases per 1,000 patient-days. 58.1%
patients were male and the median age was 40 years
old being cancer the most frequent associated underlying
disease. C. albicans (52.2%), followed by C. parapsilo-
sis (22.1%), C. tropicalis (14.8%) and C. glabrata (6.6%)
were the more frequent species. Among 100 isolates viable
for susceptibility tests 100% were susceptible to AMB (MIC
90 = 1.0mg/L) and CAS (MIC 90 = 0.064mg/L); 98% to VOR
(MIC 90 = 0.008mg/L); 91% to FLU (MIC90 = 0.5mg/L); and
66% to ITRA (MIC 90 = 0.125mg/L).
Posaconazole MIC90was 0.032mg/mL. The percentage of
essential agreement (EA) and categorical agreement (CA)
between broth micro dilution and other methodologies were
>93%, except for itraconazole (EA 80%, CA 70%). CA between
Sensititre Yeast-One versus disk diffusion and E-test versus
disk diffusion for FLU were respectively: (94%; 95%) and for
VOR(96%,98%). Minor errors accounted for the majority of
categorical errors.
Conclusion: Candidemia by C. albicans still the majority
of episodes in our Hospital but non-albicans C species are
a growing problem and its susceptibility should be closed
monitored even though overall resistance still very low. Disk
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iffusion and E-test had good CA and may be an alternative
ethodology for routine Latin America laboratories.
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revalence of Cryptococcal meningitis among HIV
eropositive patients in Georgia
. Gatserelia ∗, L. Sharvadze, M. Karchava, L. Dzigua, N.
vali, N. Badridze, T. Tsertsvadze
Infectious Diseases, AIDS and Clinical Immunology Research
enter, Tbilisi, Georgia
Background: Cryptococcal meningitis is a frequently
bserved opportunistic fungal infection in HIV seropositive
atients in Georgia and an important cause of mortality
mong these patients. This study estimates the prevalence
f cryptococcal disease in Georgia in 2003-2008 among
uman immunodeﬁciency virus (HIV)-infected patients who
ere at risk.
Methods: Numerator data were generated by surveying
ll HIV infected patients in Georgia during 2003- 2008 years.
routine serum cryptococcal antigen screening was per-
ormed on 920 HIV-positive/AIDS patients by ELISA (Premier
eridian, Italy) to improve the prognosis of cryptococcal
eningitis in HIV-infected patients through earlier diagno-
is. The cerebrospinal ﬂuid (CSF) samples were processed
or ELISA testing after preliminary microscopic examination,
omprising wet mount, Indian ink.
Results: Cryptococcal antigen was detected in the sera of
03 (11.2%) of them. Cerebrospinal ﬂuid was obtained from
8 of these 103 patients and the presence of Cryptococcus
eoformans was demonstrated by direct microscopy in 64
66%) of them. This represents 7% of the originally screened
IV seropositive group. The incidence of cryptococcal isola-
ion was in the 30-45 age group and predominantly affected
ere male patients (59 from 64).
Conclusion: In Georgia prevalence of Cryptococcal
eningitis among HIV seropositive patients is about 7%.
e found some relationship between age, gender and
revalence of Cryptococcal meningitis among HIV infected
atients. The routine mycological surveillance is required
or HIV/AIDS patients to help in an early diagnosis and appro-
riate therapy.
oi:10.1016/j.ijid.2010.02.1762
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linical analysis of 92 patients with Fungaemia - data from
ational survey in Slovakia
. Drgona1,∗, J. Trupl2, H. Hupkova3
Comenius University and National Cancer Institute,
ratislava, Slovakia
AlphaMedical s.r.o., Bratislava, Slovakia
Comenius University, Bratislava, SlovakiaBackground: A prospective national survey on fungaemia
as done during 2005-2007 in Slovakia. The increasing inci-
ence of fungaemia and candidaemia was documented (2.57
nd 2.16/100.000/year, respectively) comparing previous
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urvey. 38% of cases of candidaemia were caused by C. albi-
ans and 62% by non-albicans strains.
Methods: 92 episodes in 92 patients with fungaemia and
vailable clinical data were analysed according to data from
RFs. Informations about risk factors, antifungal treatment
nd outcome 4 weeks after the onset of infection were col-
ected.
Results: All patients except 16.3% were adults >18 years
ld. Majority of patients were hospitalized on ICU (59.7%);
3.4% of patients had cancer and 16.3% had haematological
alignancy. 20% of patients were neutropenic at the onset
f candidaemia. Previous antibacterial treatment (93.4%),
nserted central venous catheter (83.6%), total parenteral
utrition (55.4%), surgical procedure (52%) and colonisation
ith Candida spp. were the most common risk factors asso-
iated with candidaemia. Fluconazole was the preferred
st line drug (58.6% of all treated patients) followed by
oriconazole (18.4%) and Amphotericin B (10.8%). 6 patients
6.5%) did not receive any antifungal therapy - 2/6 died and
/6 survived.
Fungaemia-related and candidaemia-related mortality
as 33.7% and 27.2%, respectively. 16/25 (64%) deaths were
ue to candidaemia caused by non-albicans candida strains
nd 9/25 (36%) were associated with C.albicans.
Conclusion: Mortality of patients with candidaemia
eﬂects the epidemiological trend in Slovakia where major-
ty of cases are caused by non-albicans strains. The choice of
ntifungal therapy should be in concordance with epidemi-
logical data.
oi:10.1016/j.ijid.2010.02.1763
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Background: To describe the percentage of Cryptococ-
us neoformans and Cryptococcus gattii encountered in our
ospital, a 2500-bed teaching hospital of São Paulo, and
o compare minimal inhibitory concentrations to different
ntifungal drugs.
Methods: Consecutive and no duplicate clinical isolates
ecovered from patients with infections (meningitis, cryp-
ococcaemia, pneumonia and peritonitis) between 2006 and
008 were included for analysis. Identiﬁcation to the species
evel was performed by conventional methods based on
rowth appearance on Sabouraud dextrose agar at 37 ◦C,
A
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roduction of urease and the presence of a capsule. Results
ere conﬁrmed using the API 20C (bioMerieux, St Louis,
SA). L-canavanine-glycine-bromothymol blue agar (CGB)
as used to distinguish C. gattii from C. neoformans. Min-
mal inhibitory concentrations (MIC) to amphotericin B,
aspofungin, 5-ﬂuorocytosine, posaconazole, ﬂuconazole,
traconazole and voriconazole were determined using Sen-
ititre Yeast-One Y8TM (TREK Diagnostic Systems, Cleveland,
SA).
Results: In the study period 43 isolates were included.
hirty three (77%) were C. neoformans and 10 (23%) were
. gatti. C. neoformans MIC 50/90 for antifungal drugs were
s follow: amphotericin B.(0.5mg/L -1mg/L,) caspofungin
16mg/L-16mg/L), posaconazol (0.064mg/L-0.25mg/L),
uconazole, (4mg/L-16mg/L); itraconazol (0.125mg/L-
.5mg/L) and voriconazol (0.032mg/L-0.125mg/L) C.
atti MIC 50/90mg/L for antifungal drugs were as
ollow: amphotericin: (0.5 -1mg/L); caspofungin (16mg/L-
2mg/L); posaconazole (0.125mg/L-0.25mg/l); ﬂucona-
ole: (8mg/L-16mg/L); itraconazole (0.25mg/L-0.5mg/L)
nd for voriconazole (0.125mg/L-0.25 mg/L). Fluconazole
ICs equal or higher than 16mg/L was observed among 40%
f C. gattii and only 18% among C. neoformans isolates.
Conclusion: Species identiﬁcation among Cryptococcus
pp isolates is an important epidemiological tool and should
e done in a routine basis. C gattii showed higher ﬂucona-
ole MICs and it should be closed monitored.
oi:10.1016/j.ijid.2010.02.1764
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accharomyces fungemia associated with esophageal dis-
ase identiﬁed by D1/D2 Ribosomal RNA gene sequence
. Cheema1,∗, J. Farrell 2, C. Kurtzman3
University of Illinois College of Medicine at Peoria, Peoria,
L, USA
OSF St. Francis, Peoria, IL, USA
National Center for Agricultural Utilization Research, ARS,
SDA, Peoria, IL, USA
Background: We describe two immunocompromised
atients with ultimately fatal esophageal pathology and Sac-
haromyces cerevisiae fungemia. Originally misidentiﬁed by
itek automated techniques, both yeast were ultimately
dentiﬁed by D1/D2 LSU rRNA gene sequence. Neither
atient had received probiotics.
Methods: Case 1: A 49-year-old intoxicated homeless
ale with a history of chronic alcoholism was admitted
or workup of hypoxia. Patient described a chronic cough
nd a 60 pound weight loss over six months. Examination
as notable for cachexia, poor dentition, and inspiratory
tidor. CT scan revealed a neck mass compromising the
atient’s airway. A PET scan demonstrated a hyperme-
abolic mass in the mediastinum with paratracheal lymph
ode uptake consistent with metastatic malignant disease.
ygosaccharomyces bailii was identiﬁed in blood cultures
rom admission and on hospital day three. Intravenous
mphotericin B treatment was initiated. Subsequent cul-
ures were negative.
Results: Case 2: An 87-year-old woman with hiatal hernia
as admitted with gastrointestinal obstruction. Examination
